PEX10
PEX10 is a protein involved in import of peroxisomal matrix proteins. This protein localizes to the peroxisomal membrane. Mutations in this gene result in phenotypes within the Zellweger spectrum of peroxisomal biogenesis disorders, ranging from neonatal adrenoleukodystrophy to Zellweger syndrome. Alternative splicing results in two transcript variants encoding different isoforms.
Full Name
Peroxisomal Biogenesis Factor 10
Function
Somewhat implicated in the biogenesis of peroxisomes.
Biological Process
Peroxisome organizationManual Assertion Based On ExperimentIDA:UniProtKB
Protein import into peroxisome matrixManual Assertion Based On ExperimentIDA:UniProtKB
Protein import into peroxisome matrixManual Assertion Based On ExperimentIDA:UniProtKB
Cellular Location
Peroxisome membrane
Involvement in disease
Peroxisome biogenesis disorder complementation group 7 (PBD-CG7):
A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).
Peroxisome biogenesis disorder 6A (PBD6A):
A fatal peroxisome biogenesis disorder belonging to the Zellweger disease spectrum and clinically characterized by severe neurologic dysfunction with profound psychomotor retardation, severe hypotonia and neonatal seizures, craniofacial abnormalities, liver dysfunction, and biochemically by the absence of peroxisomes. Additional features include cardiovascular and skeletal defects, renal cysts, ocular abnormalities, and hearing impairment. Most severely affected individuals with the classic form of the disease (classic Zellweger syndrome) die within the first year of life.
Peroxisome biogenesis disorder 6B (PBD6B):
A peroxisome biogenesis disorder that includes neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD), two milder manifestations of the Zellweger disease spectrum. The clinical course of patients with the NALD and IRD presentation is variable and may include developmental delay, hypotonia, liver dysfunction, sensorineural hearing loss, retinal dystrophy and vision impairment. Children with the NALD presentation may reach their teens, while patients with the IRD presentation may reach adulthood. The clinical conditions are often slowly progressive in particular with respect to loss of hearing and vision. The biochemical abnormalities include accumulation of phytanic acid, very long chain fatty acids (VLCFA), di- and trihydroxycholestanoic acid and pipecolic acid.
A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).
Peroxisome biogenesis disorder 6A (PBD6A):
A fatal peroxisome biogenesis disorder belonging to the Zellweger disease spectrum and clinically characterized by severe neurologic dysfunction with profound psychomotor retardation, severe hypotonia and neonatal seizures, craniofacial abnormalities, liver dysfunction, and biochemically by the absence of peroxisomes. Additional features include cardiovascular and skeletal defects, renal cysts, ocular abnormalities, and hearing impairment. Most severely affected individuals with the classic form of the disease (classic Zellweger syndrome) die within the first year of life.
Peroxisome biogenesis disorder 6B (PBD6B):
A peroxisome biogenesis disorder that includes neonatal adrenoleukodystrophy (NALD) and infantile Refsum disease (IRD), two milder manifestations of the Zellweger disease spectrum. The clinical course of patients with the NALD and IRD presentation is variable and may include developmental delay, hypotonia, liver dysfunction, sensorineural hearing loss, retinal dystrophy and vision impairment. Children with the NALD presentation may reach their teens, while patients with the IRD presentation may reach adulthood. The clinical conditions are often slowly progressive in particular with respect to loss of hearing and vision. The biochemical abnormalities include accumulation of phytanic acid, very long chain fatty acids (VLCFA), di- and trihydroxycholestanoic acid and pipecolic acid.
View more
Anti-PEX10 antibodies
+ Filters
Loading...
Target: PEX10
Host: Mouse
Antibody Isotype: IgG2b, κ
Specificity: Human
Clone: 1B8
Application*: E, WB
More Infomation
Hot products 
-
Mouse Anti-ALB Recombinant Antibody (V2-55272) (CBMAB-H0819-FY)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CBC05) (CBMAB-CR005LY)
-
Mouse Anti-ADAM12 Recombinant Antibody (V2-179752) (CBMAB-A1114-YC)
-
Mouse Anti-C4B Recombinant Antibody (CBYY-C2996) (CBMAB-C4439-YY)
-
Mouse Anti-C1QC Recombinant Antibody (CBFYC-0600) (CBMAB-C0654-FY)
-
Mouse Anti-CD83 Recombinant Antibody (HB15) (CBMAB-C1765-CQ)
-
Mouse Anti-ACE2 Recombinant Antibody (V2-179293) (CBMAB-A0566-YC)
-
Mouse Anti-ADIPOR1 Recombinant Antibody (V2-179982) (CBMAB-A1368-YC)
-
Rabbit Anti-DLK1 Recombinant Antibody (9D8) (CBMAB-D1061-YC)
-
Mouse Anti-CD19 Recombinant Antibody (CBXC-1224) (CBMAB-C1491-CQ)
-
Mouse Anti-CD33 Recombinant Antibody (P67.6) (CBMAB-C10189-LY)
-
Rabbit Anti-AKT3 Recombinant Antibody (V2-12567) (CBMAB-1057-CN)
-
Mouse Anti-BRD3 Recombinant Antibody (CBYY-0801) (CBMAB-0804-YY)
-
Mouse Anti-APC Recombinant Antibody (CBYC-A661) (CBMAB-A3036-YC)
-
Mouse Anti-14-3-3 Pan Recombinant Antibody (V2-9272) (CBMAB-1181-LY)
-
Mouse Anti-DMPK Recombinant Antibody (CBYCD-324) (CBMAB-D1200-YC)
-
Rat Anti-CCR2 Recombinant Antibody (475301) (CBMAB-C1338-LY)
-
Rabbit Anti-ENO2 Recombinant Antibody (BA0013) (CBMAB-0272CQ)
-
Rabbit Anti-ALDOA Recombinant Antibody (D73H4) (CBMAB-A2314-YC)
-
Mouse Anti-ACLY Recombinant Antibody (V2-179314) (CBMAB-A0610-YC)
For Research Use Only. Not For Clinical Use.
(P): Predicted
* Abbreviations
- AActivation
- AGAgonist
- APApoptosis
- BBlocking
- BABioassay
- BIBioimaging
- CImmunohistochemistry-Frozen Sections
- CIChromatin Immunoprecipitation
- CTCytotoxicity
- CSCostimulation
- DDepletion
- DBDot Blot
- EELISA
- ECELISA(Cap)
- EDELISA(Det)
- ESELISpot
- EMElectron Microscopy
- FFlow Cytometry
- FNFunction Assay
- GSGel Supershift
- IInhibition
- IAEnzyme Immunoassay
- ICImmunocytochemistry
- IDImmunodiffusion
- IEImmunoelectrophoresis
- IFImmunofluorescence
- IGImmunochromatography
- IHImmunohistochemistry
- IMImmunomicroscopy
- IOImmunoassay
- IPImmunoprecipitation
- ISIntracellular Staining for Flow Cytometry
- LALuminex Assay
- LFLateral Flow Immunoassay
- MMicroarray
- MCMass Cytometry/CyTOF
- MDMeDIP
- MSElectrophoretic Mobility Shift Assay
- NNeutralization
- PImmunohistologyp-Paraffin Sections
- PAPeptide Array
- PEPeptide ELISA
- PLProximity Ligation Assay
- RRadioimmunoassay
- SStimulation
- SESandwich ELISA
- SHIn situ hybridization
- TCTissue Culture
- WBWestern Blot
Online Inquiry




